Revamped French agency to put the emphasis on post-authorisation monitoring
This article was originally published in SRA
Executive Summary
France's restructured healthcare products regulatory agency, which is expected to be fully operational in its new incarnation by next spring, will be putting the emphasis firmly on the post-authorisation monitoring of the safety and efficacy of medicines and medical devices1.